- Home
- GNW vs NAMS Comparison
GNW vs NAMS Comparison
Compare GNW & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNW
- NAMS
- Stock Information
- Founded
- GNW 1871
- NAMS 2019
- Country
- GNW United States
- NAMS Netherlands
- Employees
- GNW N/A
- NAMS N/A
- Industry
- GNW Life Insurance
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- GNW Finance
- NAMS Health Care
- Exchange
- GNW Nasdaq
- NAMS Nasdaq
- Market Cap
- GNW 3.5B
- NAMS 3.1B
- IPO Year
- GNW 2004
- NAMS N/A
- Fundamental
- Price
- GNW $8.64
- NAMS $37.08
- Analyst Decision
- GNW Buy
- NAMS Strong Buy
- Analyst Count
- GNW 1
- NAMS 10
- Target Price
- GNW $10.00
- NAMS $44.80
- AVG Volume (30 Days)
- GNW 4.3M
- NAMS 1.2M
- Earning Date
- GNW 11-05-2025
- NAMS 11-05-2025
- Dividend Yield
- GNW N/A
- NAMS N/A
- EPS Growth
- GNW 512.33
- NAMS N/A
- EPS
- GNW 0.44
- NAMS N/A
- Revenue
- GNW $7,261,000,000.00
- NAMS $35,243,000.00
- Revenue This Year
- GNW N/A
- NAMS N/A
- Revenue Next Year
- GNW N/A
- NAMS N/A
- P/E Ratio
- GNW $17.71
- NAMS N/A
- Revenue Growth
- GNW N/A
- NAMS 4.91
- 52 Week Low
- GNW $5.99
- NAMS $14.06
- 52 Week High
- GNW $9.15
- NAMS $41.47
- Technical
- Relative Strength Index (RSI)
- GNW 53.01
- NAMS 57.92
- Support Level
- GNW $8.29
- NAMS $35.42
- Resistance Level
- GNW $8.94
- NAMS $40.74
- Average True Range (ATR)
- GNW 0.21
- NAMS 2.19
- MACD
- GNW 0.02
- NAMS -0.32
- Stochastic Oscillator
- GNW 55.56
- NAMS 46.37
About GNW Genworth Financial Inc
Genworth Financial Inc is a diversified insurance holding company that provides various mortgage and life insurance products. The company has three main operating business segments: Enact, Life and Annuities segment and Long-Term Care Insurance. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. Majority of the revenue is generated by the Enact segment. The company earns maximum of its revenue in the United States.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.